Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: PROSTVAC, Therion.

Christian Doehn1, Dieter Jocham

  • 1Department of Urology, University of Lübeck Medial School, Germany. doehn@medinf.mu-luebeck.de

Current Opinion in Molecular Therapeutics
|November 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Current Data from the National Registry for Urothelial Cancer (UroNAT) by d-uo].

Aktuelle Urologie·2026
Same author

[7-Year Data on Penile Carcinoma from the VERSUS Study by d-uo].

Aktuelle Urologie·2026
Same author

[Early Detection of Prostate Cancer: Current Real-World Data from the VERSUS Study by d-uo].

Aktuelle Urologie·2026
Same author

[Current Data from the National Registry for Prostate Cancer (ProNAT) by d-uo].

Aktuelle Urologie·2026
Same author

[Healthcare Research in Renal Cell Cancer: 7-Year-Data from the VERSUS Study by d-uo].

Aktuelle Urologie·2026
Same author

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

Cancers·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

PROSTVAC is an investigational immunotherapeutic vaccine targeting prostate-specific antigen for prostate cancer treatment. Clinical trials were ongoing in the early 2000s to evaluate its potential efficacy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccine Development

Background:

  • Prostate cancer remains a significant health concern globally.
  • The development of effective immunotherapies is crucial for improving patient outcomes.
  • Prostate-specific antigen (PSA) is a well-established biomarker and therapeutic target in prostate cancer.

Purpose of the Study:

  • To evaluate the potential of PROSTVAC, an immunotherapeutic vaccine, in treating prostate cancer.
  • To assess the safety and efficacy of PROSTVAC through clinical trials.

Main Methods:

  • PROSTVAC is an immunotherapeutic vaccine developed by Therion Biologics.
  • The vaccine targets prostate-specific antigen (PSA).
  • Clinical trials, specifically Phase II, were initiated in February 2000 and expanded by October 2001.

Related Experiment Videos

Main Results:

  • Phase II clinical trials for PROSTVAC commenced in February 2000.
  • By October 2001, four Phase II trials were actively underway.
  • These trials aimed to gather data on the vaccine's performance in patients.

Conclusions:

  • The progression to multiple Phase II trials indicated ongoing evaluation of PROSTVAC's therapeutic potential.
  • Further clinical data were necessary to determine the definitive efficacy and safety profile of PROSTVAC for prostate cancer treatment.